Oncology biotech company Exelixis becomes a founding member of Blue Faery’s Benefactors Council
LOS ANGELES, CA, August 18, 2019 /Neptune100/ — Blue Faery: The Adrienne Wilson Liver Cancer Association is thrilled to have Exelixis, Inc. as a founding member of its new corporate giving endeavor titled Blue Faery Benefactors Council. The national membership program consists of corporations and/or individuals committed to giving an annual charitable contribution for hepatocellular carcinoma (HCC) research, HCC educational programs, patient advocacy events and/or corporate sponsorships.
President Andrea Wilson said, “Exelixis has joined our Benefactors Council at the highest membership level — Patron. They have always been supportive of our efforts to educate and advocate for HCC patients and caregivers. We value their partnership in the fight against primary liver cancer.”
Lindsay Treadway, Senior Director, Public Affairs and Advocacy Relations, Exelixis stated, “At Exelixis, making a difference goes beyond developing medicines for patients with cancer. We make a concerted effort to support non-profit organizations that are dedicated to improving the lives of cancer patients through education, outreach and advocacy. We commend Blue Faery for the important work they do to support patients with hepatocellular carcinoma. The team at Exelixis values our partnership, and we are honored to serve on Blue Faery’s Benefactors Council as a founding member.”
About Blue Faery
Founded in 2002, the mission of Blue Faery is to prevent, treat and cure primary liver cancer through research, education and advocacy. Blue Faery’s HCC patient education brochure is free for patients, their families and their healthcare providers. To serve the needs of HCC patients worldwide, Blue Faery’s website translates into 10 languages including Chinese, Hindi, Korean and Spanish. Blue Faery hosts an online Liver Cancer Community for patients and caregivers and gives an annual award to recognize researchers who have made significant contributions in the advancement of scientific knowledge in the diagnosis, treatment, prevention or understanding of primary liver cancer.
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery — all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.